hyperCORE International Strengthens Leadership Team with Key Executive Appointments

hyperCORE International, a collaborative network of clinical trial sites across North America, has announced significant updates to its executive leadership team with the appointment of Jeffrey Smyth as Vice President and Olivia McIver as Treasurer. These strategic additions strengthen the organization's governance structure and ensure continued alignment with hyperCORE's mission of driving efficiency and excellence across its collective partner site networks.

Jeffrey Smyth, who serves as President and Executive Director of partner site network TrueBlue Clinical Research, brings extensive leadership experience to his new role as Vice President. Olivia McIver, currently Director of Clinical Operations at partner site network Applied Research Center, assumes the position of Treasurer. In their new capacities, Smyth and McIver will provide complementary expertise to support hyperCORE's ongoing growth initiatives, playing key roles in overseeing financial stewardship and supporting long-term sustainability for the organization.

The executive appointments come as hyperCORE continues to expand its network of leading clinical research organizations. The network's partner sites include AGA Clinical Trials; Alcanza Clinical Research; Apex Trials; Applied Research Center; Atlas Clinical Research; CaRe Clinics; Epic Medical Research; FOMAT Medical Research; TrueBlue Clinical Research; and QCR Network. Each independently operated network participates in harmonized operational frameworks that streamline study delivery at scale, creating efficiencies across the clinical research landscape.

Nicholas Focil, President of hyperCORE, emphasized the strategic importance of these appointments. hyperCORE's strength lies in its ability to unify best-in-class research sites through shared operational excellence. As we continue to grow, having a dedicated and strategic Vice President and integrated board Treasurer is essential to guide our leadership framework and maintain our strategic mobility across our industry.

These new appointments complement the existing leadership structure, with Nicholas Focil, CEO of FOMAT Medical Research, continuing to serve as President, and Mark Scullion, CEO of Atlas Clinical Research, maintaining his role as Secretary. This experienced leadership team will guide hyperCORE through its next phase of growth and development.

hyperCORE International represents a substantial force in clinical research, boasting over 80 active trial sites across five countries and two continents. The network's partners have collectively completed more than 7,500 studies involving over 150,000 randomized participants. This scale, combined with harmonized operational frameworks, enables hyperCORE to optimize efficiency, standardization, and excellence across its member organizations.

The organization remains committed to advancing clinical research through safe, ethical, and timely studies, efficient enrollment processes, and superior retention rates. These capabilities are further enhanced by member sites' recognition through top-tier awards for performance, quality, and innovation. The strengthened executive team positions hyperCORE to continue delivering on its mission while adapting to the evolving needs of the clinical research industry.